Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEFCTP)

• Drug Name: Glufosfamide Drug Info
• Synonyms: Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 3	[1]
Ovarian cancer	2C73	Discontinued in Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 123628
  CAS Number: CAS 132682-98-5
  TTD Drug ID: DMEFCTP

Molecule-Related Drug Atlas

Drug(s) Targeting DNA synthesis (DNA synth)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nelarabine	DMB6VEG	leukaemia	2A60-2B33	Approved	[4]
acelarin	DMY96O3	Biliary tract cancer	2C17	Phase 3	[1]
FF-10502-01	DMX5290	Lymphoma	2A80-2A86	Phase 1	[1]
TAR-200	DMSQZEP	Bladder cancer	2C94	Phase 1	[1]
CLOTURIN	DMKFMYR	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[5]
EPD-clofarabine	DM149HL	Solid tumour/cancer	2A00-2F9Z	Terminated	[6]

Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[7]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[8]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[9]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[10]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[11]
Carboplatin	DMG281S	Adenocarcinoma	2D40	Approved	[12]
Busulfan	DMXYJ9C	Chronic myelogenous leukaemia	2A20.0	Approved	[13]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[14]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[15]
Dacarbazine	DMNPZL4	Adenocarcinoma	2D40	Approved	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA synthesis (DNA synth)	TTUBNVO	NOUNIPROTAC	Inhibitor	[1]
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [3] A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9(8):625-33.
• [4] Nelarabine. Drugs. 2008;68(4):439-47.
• [5] Inhibition of biosynthetic processes in P388 and Ehrlich ascites cells by cloturin. Drugs Exp Clin Res. 1988;14(9):575-80.
• [6] 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
• [7] Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
• [8] Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
• [9] 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
• [10] Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
• [11] O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
• [12] Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
• [13] DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
• [14] Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
• [15] Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
• [16] Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.